116 related articles for article (PubMed ID: 38109944)
1. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
Linge A; Patil S; Grosser M; Lohaus F; Gurtner K; Kemper M; Gudziol V; Haim D; Nowak A; Tinhofer I; Zips D; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Gani C; Jöhrens K; Baretton GB; Löck S; Baumann M; Krause M;
Radiother Oncol; 2024 Feb; 191():110055. PubMed ID: 38109944
[TBL] [Abstract][Full Text] [Related]
2. Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
Patil S; Tawk B; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S; Linge A;
Radiother Oncol; 2022 Feb; 167():300-307. PubMed ID: 34999136
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
Patil S; Linge A; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S;
Radiother Oncol; 2022 Jun; 171():91-100. PubMed ID: 35429503
[TBL] [Abstract][Full Text] [Related]
4. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
5. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M;
Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686
[TBL] [Abstract][Full Text] [Related]
6. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
7. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
[TBL] [Abstract][Full Text] [Related]
8. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
[TBL] [Abstract][Full Text] [Related]
9. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Lohaus F; Linge A; Tinhofer I; Budach V; Gkika E; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; von Neubeck C; Baretton GB; Löck S; Thames HD; Krause M; Baumann M;
Radiother Oncol; 2014 Dec; 113(3):317-23. PubMed ID: 25480095
[TBL] [Abstract][Full Text] [Related]
10. Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy.
Linge A; Schmidt S; Lohaus F; Krenn C; Bandurska-Luque A; Platzek I; von Neubeck C; Appold S; Nowak A; Gudziol V; Buchholz F; Baretton GB; Baumann M; Löck S; Krause M
Clin Transl Radiat Oncol; 2019 May; 16():40-47. PubMed ID: 30993218
[TBL] [Abstract][Full Text] [Related]
11. Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy.
Linge A; Löck S; Krenn C; Appold S; Lohaus F; Nowak A; Gudziol V; Baretton GB; Buchholz F; Baumann M; Krause M
Clin Transl Radiat Oncol; 2016 Dec; 1():19-26. PubMed ID: 29657990
[TBL] [Abstract][Full Text] [Related]
12. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
[TBL] [Abstract][Full Text] [Related]
13. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
14. Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
Schmidt S; Linge A; Grosser M; Lohaus F; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Baumann M; Krause M; Löck S;
J Mol Diagn; 2020 Jun; 22(6):801-810. PubMed ID: 32247864
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome analysis reveals the prognostic and immune infiltration characteristics of glycolysis and hypoxia in head and neck squamous cell carcinoma.
Liu J; Lu J; Li W
BMC Cancer; 2022 Mar; 22(1):352. PubMed ID: 35361159
[TBL] [Abstract][Full Text] [Related]
16. Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.
Rabasco Meneghetti A; Zwanenburg A; Linge A; Lohaus F; Grosser M; Baretton GB; Kalinauskaite G; Tinhofer I; Guberina M; Stuschke M; Balermpas P; von der Grün J; Ganswindt U; Belka C; Peeken JC; Combs SE; Böke S; Zips D; Troost EGC; Krause M; Baumann M; Löck S
Sci Rep; 2022 Oct; 12(1):16755. PubMed ID: 36202941
[TBL] [Abstract][Full Text] [Related]
17. SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.
De-Colle C; Mönnich D; Welz S; Boeke S; Sipos B; Fend F; Mauz PS; Tinhofer I; Budach V; Jawad JA; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Bayer C; Belka C; Pigorsch S; Combs SE; Lohaus F; Linge A; Krause M; Baumann M; Zips D; Menegakis A
Clin Transl Radiat Oncol; 2017 Aug; 5():28-36. PubMed ID: 29594214
[TBL] [Abstract][Full Text] [Related]
18. [MicroRNAs in Prediction of Response to Radiotherapy in Head and Neck Cancer Patients - Pilot Study].
Ahmad P; Slavík M; Šána J; Hermanová M; Šlampa P; Smilek P; Kazda T; Slabý O
Klin Onkol; 2018; 31(Supplementum1):137-139. PubMed ID: 29808687
[TBL] [Abstract][Full Text] [Related]
19. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
20. MTDH enhances radiosensitivity of head and neck squamous cell carcinoma by promoting ferroptosis based on a prognostic signature.
Cao X; Ge Y; Yan Z; Hu X; Peng F; Zhang Y; He X; Zong D
J Radiat Res; 2024 Jan; 65(1):10-27. PubMed ID: 37981296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
